StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc.

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3078% above fair value
$17.58−0.96 (-5.18%)

Close on Nov 20, 2026Market cap $4.97BP/E –Yield –

Caris Life Sciences Capital Expenditures & Capitalized Software by Quarter

Capital Expenditures & Capitalized Software ($M)

Caris Life Sciences Capital Expenditures & Capitalized Software: $17.5M in Q3 2026, up 146.5% from a year earlier.

Latest, Q3 2026
17.5
Period ended Sep 30, 2026
Change on a year earlier
+146.5%
7.10 in Q3 2025
History
9 quarters
Since Q3 2024
Sources
5
Documents cited below

Where the Q3 2026 figure comes from

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: SEC Form 10-Q (0002019410-26-000069, filed 2026-11-04) ↗

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Caris Life Sciences Capital Expenditures & Capitalized Software ($M), quarterly Q3 2024–Q3 2026 [Data set]. Compiled from Caris Life Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/cai/kpis/db-capex

See every metric in the Caris Life Sciences KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?